Rise Therapeutics Completes Enrollment for R-2487 Rheumatoid Arthritis Trial
Rise Therapeutics has completed enrollment in the four-week dose expansion cohort of its Phase 1b clinical trial for R-2487, an oral immunotherapy for rheumatoid arthritis (RA). The trial involves 40 patients and aims to evaluate the safety, efficacy, and pharmacodynamics of R-2487 in combination with standard care. The therapy is designed to induce immune tolerance and restore immune balance, offering a novel approach to treating autoimmune diseases. The company's Data Monitoring Committee has recommended the progression of clinical development, marking a significant milestone for the R-2487 program. 
